IL2 and rheumatoid arthritis: There was also no significant difference in rejection events between the groups: 14/67 (21%) patients in the ATG group and 12/67 (18%) in the IL-2 RA group experienced at least one rejection in year one post-transplant (HR=1.183; P=0.6535; Figure 3B).